Background. Recombinant activated factor VII (rFVIIa) decreases requirements for allogeneic blood transfusion and chest reexploration in patients undergoing cardiac surgery. Whether rFVIIa increases the risk of postoperative adverse events is unclear. We tested whether rFVIIa administration was associated with increased mortality and neurologic and renal morbidity in patients undergoing cardiac surgery. Risk of thromboembolic complications and the doseresponse of rFVIIa on mortality and morbidity were also evaluated.
Methods. Of 27,977 patients who had complex cardiac surgery, 164 patients (0.59%) received rFVIIa perioperatively. Using propensity-matching techniques, patients were matched to a maximum of 3 control patients. Patients who received rFVIIa were compared with control patients on risk of mortality, neurologic and renal morbidity, and thromboembolic complications, including a composite of myocardial infarction, pulmonary embolism, and deep venous thrombosis. A corresponding dose-response analysis using multivariable logistic regression was also performed.
Results. Propensity techniques successfully matched 144 patients (88%) with 359 control patients. Of patients who received rFVIIa, 40% experienced in-hospital mortality compared with 18% of control patients (odds ratio, 2.82; 98.3% confidence interval, 1.64 to 4.87; p < 0.001). Furthermore, 31% of patients treated with rFVIIa versus 17% of control patients experienced renal morbidity (odds ratio, 2.07; 98.3% confidence interval, 1.19 to 3.62; p [ 0.002); however, neurologic morbidity and thromboembolic complications were not different among groups. High-dose rFVIIa (>60 mg/kg) did not increase the risk for mortality compared with treatment with low-dose rFVIIa (<60 mg/kg).
Conclusions. Administration of rFVIIa is associated with increased mortality and renal morbidity in patients undergoing cardiac surgery.
(Ann Thorac Surg 2014;98:618-24) Ó 2014 by The Society of Thoracic Surgeons R efractory hemorrhage during complex cardiac surgery operations worsens perioperative outcomes and increases risk for mortality [1] [2] [3] . Recombinant activated factor VII (rFVIIa), licensed by the US Food and Drug Administration for prevention and treatment of bleeding in patients with hemophilia A or B and factor VII deficiency, has been used for off-label indications in a variety of clinical settings, including cardiac surgery [4] [5] [6] [7] . Administration of rFVIIa decreases requirements for allogeneic blood and blood components transfusion and chest reexploration for bleeding [8] [9] [10] [11] [12] [13] [14] . However, despite these favorable effects, the safety of rFVIIa is not well established.
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The inherent procoagulant characteristics of rFVIIa may increase the risk of serious thrombotic complications [15] . Certainly, the risk of thrombotic complications related to rFVIIa administration during cardiac surgery [16, 17] exceeds the risk of rFVIIa use in patients with hemophilia [18] . Interestingly, despite concerns of increased morbidity with rFVIIa administration, the effect of rFVIIa on postoperative renal function has not been thoroughly explored [9, 17, 19, 20] .
Although risk of thromboembolic complications has been investigated [9, 16, 17] , studies evaluating risk of mortality after cardiac surgery are limited [6, 14, 19] because they were underpowered [9, 12, 21] , lacked a control group [6, 7, 16] , examined a diverse patient population [17] , or used passive surveillance techniques so the true incidence of adverse outcomes was unknown [22] . Further, few investigations were limited to the placement of left ventricular assist device or thoracic aortic surgery, compromising the generalizability of the results [12, 16] . Importantly, whether the patient's perioperative risk profile and severity of illness affects the risk of mortality and morbidity associated with rFVIIa administration has not been examined. Thus, further analysis is needed to better define the effect of rFVIIa on postoperative mortality and morbidity and improve our understanding of the risk-tobenefit ratio associated with rFVIIa treatment.
The purpose of this investigation was to determine whether administration of rFVIIa increases the risk for mortality and, neurologic and renal morbidity after cardiac surgery. Further, we assessed the contribution of the patient's perioperative risk profile to risk of adverse outcome and whether rFVIIa dose affects the risk of postoperative complications.
Patients and Methods
We used data from the Cardiothoracic Anesthesia Patient Registry of the Department of Cardiothoracic Anesthesia and Cardiovascular Information Registry of the Heart and Vascular Institute at the Cleveland Clinic. Data were prospectively collected in a standardized fashion according to strict definitions of preoperative characteristics, intraoperative variables, and postoperative outcomes. The institutional review board approved the study protocol.
Anesthetic and Surgical Management
The following complex cardiac surgical procedures were included: multiple valve replacements, thoracic aortic procedures, heart and lung transplants, and mechanical circulatory support. Routine strategies for implementation of cardiopulmonary bypass, antegrade or retrograde cold blood cardioplegia, heparinization, and antifibrinolytic therapy using aminocaproic acid infusion were followed. Indications for rFVIIa included protracted bleeding and severe coagulopathy refractory to blood and blood component transfusion during the intraoperative or postoperative period. We administered rFVIIa intravenously in a dose of 20 to 90 mg/kg, and repeated for refractory coagulopathy.
Statistical Analysis
To control for confounding variables each patient who received rFVIIa was matched to a maximum of 3 patients who did not receive rFVIIa (control) using exactly matching and propensity score matching. Specifically, we first estimated the probability of receiving rFVIIa (ie, the propensity score) for each patient using logistic regression with rFVIIa as the outcome and using all prespecified potential confounding variables listed in Table 1 . Patients receiving rFVIIa and control patients were matched (up to 1:3) using a greedy distance matching algorithm (SAS macro: gmatch), restricting successful matches to those with the same units of red blood cell transfusion and those whose logit of the estimated propensity scores (ie, logðb p=ð1 À b pÞ estimated propensity score) were within 0.2 standard deviation on the logit of propensity score (ie, 0.2 Â 1.22 ¼ 0.244) of one another. All analyses used this subset of matched patients.
Assessment of covariable balance was performed using standardized differences (ie, difference in means or proportions divided by pooled standard deviation). Imbalance was defined as an absolute standardized difference (STD) greater than 0. ); any such covariables would have been entered into the models comparing rFVIIa and control patients on outcomes to reduce potential confounding.
Primary Outcomes
Our primary outcomes as previously described [23] were (1) all-cause in-hospital mortality; (2) neurologic morbidity, defined as new postoperative focal (aphasia, decrease in limb function, or hemiparesis confirmed by clinical findings or neurologic imaging) or global neurologic deficit (diffuse encephalopathy with >24 hours of severely altered mental status, or failure to awaken); and (3) renal morbidity, defined as postoperative anuria or oliguria (urine output <400 mL/ 24 hours) or institution of renal dialysis or ultrafiltration. Rather than analyzing the vector of outcomes as a collapsed composite of "any-versus-none," a multivariate (ie, multiple outcomes per patient) analysis simultaneously captured complete information on each component for a patient and correlations among components. The association between rFVIIa and each of the three primary outcomes was assessed individually using a "distinct effects" generalized estimating equation model with unstructured covariance matrix [24] . Imbalanced covariables after matching (STD < 0.19 in absolute value) were adjusted for in the analysis. Three sensitivity analyses were conducted using additional ways of adjusting for observed confounding variables: (1) adjustment for covariables with STD greater than 0.10 in absolute value after propensity score matching; (2) adjustment for all covariables used to estimate propensity score; and (3) adjustment for propensity score. Secondarily, we assessed treatment effect within quintiles of the propensity score. Bonferroni correction for multiple comparisons was used to control type I error at 0.05, thus a probability value of less than 0.017 was considered significant for each primary outcome (ie, 0.05/3 ¼ 0.017).
In addition, we conducted a sensitivity analysis comparing rFVIIa and control patients based on the AKIN criteria for acute kidney injury previously defined in the literature [25] . We used a multivariable logistic regression model with a backward selection procedure (alpha-toenter ¼ 0.20 and alpha-to-stay ¼ 0.30), in which preoperative creatinine and all potential confounders used for the matching were considered for inclusion.
For the primary outcomes in which we observed a significant difference between matched rFVIIa and control patients, a corresponding "dose-response" analysis using multivariable logistic regression was conducted. All potential confounders used for the propensity score matching were considered for and included in the model through use of a backward selection procedure. Because low versus high dose of rFVIIa is not clearly defined, 60 mg/kg dose was used as a cutoff.
Secondary Outcomes
Propensity-score matched rFVIIa and control patients were compared on total intubation time (days), total intensive care unit length of stay (days), duration of hospitalization (days), and a composite outcome of deep venous thrombosis, pulmonary embolism, and myocardial infarction, using multivariable logistic regression or Cox proportional hazard regression, as appropriate. Patients who died before the event (extubation or discharge) were considered failures in the corresponding analysis, 
Results
Of 27,977 adult patients who underwent major cardiovascular surgery between January 2006 and December 2011, 164 (0.59%) patients received rFVIIa treatment perioperatively. One hundred forty-four (88%) of these patients were successfully matched with 359 control patients. Among those, 41 (28%) received rFVIIa intraoperatively, 92 (64%) postoperatively, and 11 (8%) both intraoperatively and postoperatively. Seventy-five (52%) patients received more than one dose of rFVIIa. Patients who received rFVIIa were in worse medical condition and with more comorbidities including heart failure, end-stage kidney disease, requiring emergency surgery, and receiving more blood transfusions (Table 1 , left). Propensity score techniques successfully balanced most variables in the matched subset, which were used to assess the association with the outcomes (Table 1, right) . Amounts of fresh frozen plasma, platelets, and cryoprecipitate transfusions remained slightly imbalanced (STD > 0.19) between groups. To be conservative, we adjusted for these factors when comparing groups on the outcomes.
Of the propensity-matched patients, 40% of patients who received rFVIIa experienced in-hospital mortality versus 18% of control patients after adjusting for imbalanced covariables and within-patient correlation (odds ratio, 2.82; 98.3% confidence interval, 1.64 to 4.87; p < 0.001; Fig 1) . Similarly, 31% of patients treated with rFVIIa experienced renal morbidity versus 17% of control patients (odds ratio, 2.07; 98.3% confidence interval, 1.19 to 3.62; p ¼ 0.002). However, neurologic morbidity was not increased in patients who received rFVIIa (17% versus 11%; odds ratio, 1.60; 98.3% confidence interval, 0.81 to 3.15; p ¼ 0.10). Additional ways of risk adjustment yielded similar results (Table  2) . Furthermore, associations depended on quintiles of the propensity score. For each primary outcome, the association was stronger for patients at lower risk (lower quintiles; Fig 2) .
The sensitivity analysis of acute kidney injury using AKIN criteria provided consistent results. Both precreatinine and postcreatinine levels were available for 455 patients, including 128 rFVIIa patients and 327 control patients. Forty-one (32%) rFVIIa patients and 77 (24%) control patients experienced stage 1 injury; no patients experienced stage 2 or 3 injury. We found that patients who were treated with rFVIIa were 1.80 times (95% confidence interval, 1.04 to 3.12) more likely to experience acute kidney injury within 48 hours after surgery compared with control patients.
The secondary outcome analysis found no difference in risk of deep venous thrombosis, pulmonary embolism, or myocardial infarction between groups. Patients receiving rFVIIa were more likely to require mechanical ventilation and to remain in the intensive care unit and hospital postoperatively ( Table 3) .
The median dose for the overall patient population group was 94 mg/kg (interquartile range, 78 to 173 mg/kg). 
Comment
Our analysis found that patients undergoing cardiac surgery who require rFVIIa perioperatively are severely ill and require high-risk surgery complicated by coagulopathy, refractoriness to massive blood, and blood component transfusion. Perioperative administration of rFVIIa was associated with increased risk of mortality, renal morbidity, and prolonged hospital stay. In contrast, thromboembolic complications were not increased. Additionally, rFVIIa did not have a dose-dependent effect on postoperative outcomes. The cause of increased mortality with rFVIIa administration is unclear; however, increased renal morbidity with rFVIIa use may contribute, at least in part, to higher mortality [26, 27] . Surprisingly, thromboembolic events were not increased with rFVIIa. Stratification of patients by perioperative risk profile and severity of illness using quintile propensity analysis demonstrated a consistent trend of increased mortality in all quintiles, with the exception of patients with the highest perioperative risk.
The results of our investigation conflict with another retrospective study, which reported no mortality difference, although a trend toward increased mortality was suggested [14] . However, that report [14] was limited by poorly described matching techniques, which resulted in an imbalance in preoperative EuroSCOREs. This suggested that control patients may have been at higher risk than patients receiving rFVIIa. Our analysis, in contrast, matched patients on multiple variables representing patient comorbidities and perioperative variables, ensuring well-balanced propensity-matched groups. Moreover, several sensitivity analyses produced consistent results. Patients treated with rFVIIa experienced more kidney injury for unclear reasons. With a dual tissue factordependent and independent mechanism of action, rFVIIa restores thrombin production and augments hemostasis at the site of vessel injury [28] . Thus, increased tissue factor expression after cardiopulmonary bypass [29] with inflammatory modulating properties of rFVIIa [30] may promote a procoagulant state. These prothrombotic effects in the renal vascular bed and increased tissue factor expression in renal glomeruli may increase renal morbidity [31] . Interestingly, risk of renal morbidity was increased in all quintile subsets of patients, except for patients with the highest risk profile.
Investigations of the risk of stroke, myocardial infarction, and pulmonary embolism associated with rFVIIa administration have reported mixed results [9, 17, 20, 22] . Our investigation found no difference in the risk of neurologic injury or thromboembolic complications, perhaps because the severity of patients' comorbidities overshadowed the risk of rFVIIa [11] . Nevertheless, the high incidence of serious complications demonstrates that the study cohort represents the highest-risk population and may not be applicable to all cardiac surgery patients.
The optimal dose of rFVIIa for treatment of coagulopathy without increasing risk of adverse events is unknown. Initial dosing recommendations for rFVIIa of 90 to 120 mg/kg in cardiac surgery were extrapolated from the treatment of patients with hemophilia [32] . Low-dose rFVIIa (10 to 60 mg/kg) [9, 12, 16] is effective [7, 12, 33, 34] and may decrease the risk of thromboembolic events [16] . Our dose-response analysis, however, found no difference in the risk of renal morbidity and mortality in patients receiving high-dose rFVIIa (>60 mg/kg) compared with low-dose rFVIIa (<60 mg/kg). However, only 14% of patients received low-dose rFVIIa, which may have limited our analysis. Similar to another investigation [34] , adverse outcomes were associated with rFVIIa regardless of dose. Benefits of low-dose rFVIIa include cost-savings, which may, however, be offset by the cost of postoperative complications [12] .
The primary limitation of the present analysis is that despite using nonparsimonious propensity-score matching, we cannot exclude the possible influence of unmeasured confounders. Second, as with any retrospective analysis, we can only identify an association rather than a cause-and-effect relationship. Third, we studied gross neurologic outcomes. Use of more sensitive outcomes, such as neurocognitive studies, may have influenced our findings. Also, use of rFVIIa is dependent on the physicians' discretion; thus, selection bias may have occurred. Our study did not differentiate between intraoperative or postoperative times of administration, thus it is possible that the timing of rFVIIa administration affected the results. A major strength of this analysis, however, is that multiple sensitivity analyses produced consistent results. Further, quintile analysis that stratified patients based on the severity of their illness adds to the strength of this study by evaluating the impact of rFVIIa on the "sickness" of the patients, providing important insight into the patient's risk of complications related to rFVIIa administration.
In conclusion, administration of rFVIIa is associated with increased mortality and renal morbidity in patients undergoing cardiac surgery. We did not find an association between administered dose of rFVIIa and risk of adverse outcome. Caution is advised in the off-label administration of rFVIIa to patients undergoing cardiac surgery. 
